Asset Details
Do you wish to reserve the book?
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
Do you wish to request the book?
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
2014
Overview
Purpose
There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically ill patients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK target attainment. The objective of this study was to analyse the effect of a dose-adaption strategy based on daily TDM on target attainment.
Methods
This was a prospective, partially blinded, and randomised controlled trial in patients with normal kidney function treated with meropenem (MEM) or piperacillin/tazobactam (PTZ). The intervention group underwent daily TDM, with dose adjustment when necessary. The predefined PK/pharmacodynamic (PK/PD) target was 100 %
f
T
>4MIC
[percentage of time during a dosing interval that the free (
f
) drug concentration exceeded 4 times the MIC]. The control group received conventional treatment. The primary endpoint was the proportion of patients that reached 100 %
f
T
>4MIC
and 100 %
f
T
>MIC
at 72 h.
Results
Forty-one patients (median age 56 years) were included in the study. Pneumonia was the primary infectious diagnosis. At baseline, 100 %
f
T
>4MIC
was achieved in 21 % of the PTZ patients and in none of the MEM patients; 100 %
f
T
>MIC
was achieved in 71 % of the PTZ patients and 46 % of the MEM patients. Of the patients in the intervention group, 76 % needed dose adaptation, and five required an additional increase. At 72 h, target attainment rates for 100 %
f
T
>4MIC
and 100 %
f
T
>MIC
were higher in the intervention group: 58 vs. 16 %,
p
= 0.007 and 95 vs. 68 %,
p
= 0.045, respectively.
Conclusions
Among critically ill patients with normal kidney function, a strategy of dose adaptation based on daily TDM led to an increase in PK/PD target attainment compared to conventional dosing.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ beta-Lactamase Inhibitors - administration & dosage
/ beta-Lactamase Inhibitors - pharmacokinetics
/ beta-Lactamase Inhibitors - pharmacology
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Male
/ Medicine
/ Original
/ Patients
/ Penicillanic Acid - administration & dosage
/ Penicillanic Acid - analogs & derivatives
/ Penicillanic Acid - pharmacokinetics
/ Penicillanic Acid - pharmacology
/ Piperacillin - administration & dosage
/ Piperacillin - pharmacokinetics
/ Pneumology/Respiratory System
/ Thienamycins - administration & dosage
